ROCHE AND EPITOMICS ENTER RABBIT MONOCLONAL ANTIBODY TECHNOLOGY RESEARCH AGREEMENT

Roche and Epitomics, Inc. today announced a research agreement granting Roche a license to Epitomics' rabbit monoclonal antibody technology (RabMab technology) for the discovery and development of monoclonal antibodies to treat cancer and other diseases. In a departure from conventional methods of biological drug discovery, which use mouse antibodies, Epitomics' unique approach utilizes monoclonal antibodies from rabbits, potentially improving the quality and efficiency of drug discovery. Epitomics will receive event payments and future royalties on worldwide sales of products developed from RabMab technology.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/ae98d714bee91686a67e6645f019c293.html)